Quantitative Longitudinal Analysis of T Cell Receptor Repertoire Expression in HIV-Infected Patients on Antiretroviral and Interleukin-2 Therapy
- 1 May 2007
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 23 (5), 741-747
- https://doi.org/10.1089/aid.2007.0209
Abstract
We have developed a single-step reverse transcriptase kinetic PCR assay (kRT-PCR) to accurately determine the expression of each of the 24 TCRβV gene families in CD8+ cells. We analyzed the long-term effects of highly active antiretroviral therapy (HAART) on the stability of the CD8+ T cell receptor (TCR) repertoire in a cohort of 15 treated and 10 untreated individuals diagnosed with human immunodeficiency virus (HIV) infection. The CD4+ TCR repertoire was studied in a second cohort receiving interleukin-2 infusions in addition to HAART. Analysis was based on kinetic (quantitative) reverse-transcription PCR (kRT-PCR) of the TCR variable B gene (TCRβV). Expression of each of the 24 Vβ families was assessed at baseline immediately after infection and following initiation of HAART at 2, 4, 12, 24, and up to 192 weeks in 24-week intervals. Statistically significant family-specific expression changes were observed between treated and untreated individuals for 10 TCRβV families. Overall, when compared to untreated patients, a more stable expression of TCR genes was observed for HAART-treated individuals. Interestingly, this difference did not correlate with either CD4 or CD8 counts, which follow the expected curves for treated and untreated patients. When we applied our quantitative analysis to IL-2-treated patients we observed a rapid polyclonal activation of the repertoire. These results suggest that homeostasis in the T cell receptor repertoire is more robust in those patients who stay on HAART for a long time and confirm the polyclonal stimulating capacity of IL-2.Keywords
This publication has 26 references indexed in Scilit:
- Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patientsJournal of Clinical Investigation, 2005
- Longitudinal analysis of B cell repertoire and antibody gene rearrangements during early HIV infectionGenes & Immunity, 2004
- Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infectionAIDS, 2003
- Pilot Study of the Effects of Intermittent Interleukin‐2 on Human Immunodeficiency Virus (HIV)–Specific Immune Responses in Patients Treated during Recently Acquired HIV InfectionThe Journal of Infectious Diseases, 2002
- A Randomized, Controlled, Phase II Trial Comparing Escalating Doses of Subcutaneous Interleukin‐2 plus Antiretrovirals versus Antiretrovirals Alone in Human Immunodeficiency Virus–Infected Patients with CD4+Cell Counts ⩾350/mm3The Journal of Infectious Diseases, 2000
- Transient T Cell Receptor β‐Chain Variable Region–Specific Expansions of CD4+and CD8+T Cells during the Early Phase of Pediatric Human Immunodeficiency Virus Infection: Characterization of Expanded Cell Populations by T Cell Receptor PhenotypingThe Journal of Infectious Diseases, 2000
- Efficacy of Low‐Dose Subcutaneous Interleukin‐2 to Treat Advanced Human Immunodeficiency Virus Type 1 in Persons with ⩽250/μL CD4 T Cells and Undetectable Plasma Virus LoadThe Journal of Infectious Diseases, 1999
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Increases in CD4 T Lymphocytes with Intermittent Courses of Interleukin-2 in Patients with Human Immunodeficiency Virus Infection — A Preliminary StudyNew England Journal of Medicine, 1995
- Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIVNature, 1994